氨氯地平与依那普利联合应用对高血压合并肾病的疗效比较观察

目的比较氨氯地平分别与依那普利联合应用对肾病的疗效和安全性的观察 方法：按WHO 诊断标准对82例新诊断舒张压为95～115mmHg,收缩压〈180mmHg 的高血压病合并糖尿病肾病（HDN）患者82例并随机分为A、B 两组每组各41例进行治疗前后对比性分析.结果 两组病人经过治疗6周后,平均舒张压及平均收缩压的降低无显著差异（P〉0.10）.治疗前后通过观察指标分析A 组的HbA1c、24h 尿蛋白排泄率、血清hs-CRP 水平均明显降低（P〈0.05）. 结论：联合应用氨氯地平与依那普利或氨氯地平与氢氯噻嗪对HDN 患者的降压疗效相似,但前者在治疗早期糖尿病肾病中可延缓患者病情及肾脏损害,其安全性和耐受性较后者为佳.

ObjectiveTo observe the method of amlodipine combined with enalapril on kidney respectively. The efficacy and safety of： in 2012 March -2013 year in June,according to WHO diagnostic criteria in 82 patients with diastolic blood pressure was 95 - 115mmHg, systolic pressure 〈 180mmHg in hypertensive patients with diabetic nephropathy（HDN） patients with 82 cases and were randomly divided into A, B two groups of 41 patients each were compared before and after treatment. Results：two patients after treatment for 6weeks, the average diastolic blood pressure and systolic blood pressure reduction had no significant difference （P 〉 0.10）. Observation index analysis of A group of HbA1c, 24h urinaryprotein excretion, serum hs-CRP levels were significantly reduced by before and after treatment （P 〈 0.05）. Conclusion：the antihypertensive efficacy of combination of amlodipine andenalapril and amlodipine and hydrochlorothiazide in patients with HDN is similar, but the former in the treatment of early diabetic nephropathy can delay the disease and kidney damage,its safety and tolerability is better than the latter.